The full results from the ANCHOR-1 and ANCHOR-2 studies will be presented at an upcoming scientific conference. More on GSK's Depemokimab Development Plans Earlier this year, two phase III studies ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...